Deerfield Management’s Viking Therapeutics VKTX Stock Holding History

Deerfield Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-463,501	Closed	-$38M	–	569
2024 Q1	$38M	Sell	463,501 -815,499	-64%	-$36.3M	0.66%	35
2023 Q4	$23.8M	Hold	1,279,000	–	–	0.44%	44
2023 Q3	$14.2M	Buy	1,279,000 +154,000	+14%	+$2.2M	0.31%	50
2023 Q2	$18.2M	Hold	1,125,000	–	–	0.39%	51
2023 Q1	$18.7M	Buy	+1,125,000	New	+$11.6M	0.42%	54
2020 Q4	–	Sell	-348,441	Closed	-$2.03M	–	140
2020 Q3	$2.03M	Buy	+348,441	New	+$2.4M	0.05%	99
2018 Q4	–	Sell	-460,000	Closed	-$8.01M	–	106
2018 Q3	$8.01M	Buy	+460,000	New	+$5.47M	0.29%	78

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Deerfield Management's VKTX Position: Q2 2024 in Review

Deerfield Management sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 463,501 shares — an estimated $38M sold.

Deerfield Management first reported a position in VKTX in Q3 2018 and held it in 7 quarters. The position peaked at $38M in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

Deerfield Management reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
Deerfield Management sold 463,501 Viking Therapeutics shares in Q2 2024, an estimated $38M.
Deerfield Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 7 quarters.
Deerfield Management's Viking Therapeutics position peaked at $38M in Q1 2024.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Deerfield Management's 13F filing for Q2 2024, filed 14 Aug 2024.